We investigated the in vivo efficacy of tigecycline, a new glycylcycline (a tetracycline derivative), in the management of methicillin-resistant Staphylococcus aureus (MRSA)-infected experimental surgical wounds in rats. The main outcome measures were quantitative bacterial culture, histological examination and immunohistochemical expression of matrix metalloproteinase-9 (MMP-9) and collagen IV.
Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation / Simonetti, O., Cirioni, O., Lucarini, G., Orlando, F., Ghiselli, R., Silvestri, C., Brescini, L., Rocchi, M., Provinciali, M., Guerrieri, M., Di Primio, R., Giacometti, A., Offidani, A.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 1460-2091. - ELETTRONICO. - 67:1(2012), pp. 191-201. [10.1093/jac/dkr440]
Tigecycline accelerates staphylococcal-infected burn wound healing through matrix metalloproteinase-9 modulation
Simonetti O;Cirioni O;Lucarini G;Ghiselli R;Silvestri C;Brescini L;Guerrieri M;Di Primio R;Giacometti A;Offidani A
2012-01-01
Abstract
We investigated the in vivo efficacy of tigecycline, a new glycylcycline (a tetracycline derivative), in the management of methicillin-resistant Staphylococcus aureus (MRSA)-infected experimental surgical wounds in rats. The main outcome measures were quantitative bacterial culture, histological examination and immunohistochemical expression of matrix metalloproteinase-9 (MMP-9) and collagen IV.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
